Carmen Mikacenic1, Brenda L Price2, Susanna Harju-Baker1, D Shane O'Mahony3, Cassianne Robinson-Cohen4, Frank Radella1, William O Hahn5, Ronit Katz4, David C Christiani6,7, Jonathan Himmelfarb4, W Conrad Liles5, Mark M Wurfel1. 1. 1 Division of Pulmonary and Critical Care Medicine, Department of Medicine. 2. 2 Department of Biostatistics. 3. 3 Department of Pulmonary and Critical Care Medicine, Swedish Medical Center, Seattle, Washington. 4. 4 Kidney Research Institute, and. 5. 5 Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington. 6. 6 Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; and. 7. 7 Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts.
Abstract
RATIONALE: Improving the prospective identification of patients with systemic inflammatory response syndrome (SIRS) and sepsis at low risk for organ dysfunction and death is a major clinical challenge. OBJECTIVES: To develop and validate a multibiomarker-based prediction model for 28-day mortality in critically ill patients with SIRS and sepsis. METHODS: A derivation cohort (n = 888) and internal test cohort (n = 278) were taken from a prospective study of critically ill intensive care unit (ICU) patients meeting two of four SIRS criteria at an academic medical center for whom plasma was obtained within 24 hours. The validation cohort (n = 759) was taken from a prospective cohort enrolled at another academic medical center ICU for whom plasma was obtained within 48 hours. We measured concentrations of angiopoietin-1, angiopoietin-2, IL-6, IL-8, soluble tumor necrosis factor receptor-1, soluble vascular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas. MEASUREMENTS AND MAIN RESULTS: We identified a two-biomarker model in the derivation cohort that predicted mortality (area under the receiver operator characteristic curve [AUC], 0.79; 95% confidence interval [CI], 0.74-0.83). It performed well in the internal test cohort (AUC, 0.75; 95% CI, 0.65-0.85) and the external validation cohort (AUC, 0.77; 95% CI, 0.72-0.83). We determined a model score threshold demonstrating high negative predictive value (0.95) for death. In addition to a low risk of death, patients below this threshold had shorter ICU length of stay, lower incidence of acute kidney injury, acute respiratory distress syndrome, and need for vasopressors. CONCLUSIONS: We have developed a simple, robust biomarker-based model that identifies patients with SIRS/sepsis at low risk for death and organ dysfunction.
RATIONALE: Improving the prospective identification of patients with systemic inflammatory response syndrome (SIRS) and sepsis at low risk for organ dysfunction and death is a major clinical challenge. OBJECTIVES: To develop and validate a multibiomarker-based prediction model for 28-day mortality in critically illpatients with SIRS and sepsis. METHODS: A derivation cohort (n = 888) and internal test cohort (n = 278) were taken from a prospective study of critically ill intensive care unit (ICU) patients meeting two of four SIRS criteria at an academic medical center for whom plasma was obtained within 24 hours. The validation cohort (n = 759) was taken from a prospective cohort enrolled at another academic medical center ICU for whom plasma was obtained within 48 hours. We measured concentrations of angiopoietin-1, angiopoietin-2, IL-6, IL-8, soluble tumor necrosis factor receptor-1, soluble vascular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas. MEASUREMENTS AND MAIN RESULTS: We identified a two-biomarker model in the derivation cohort that predicted mortality (area under the receiver operator characteristic curve [AUC], 0.79; 95% confidence interval [CI], 0.74-0.83). It performed well in the internal test cohort (AUC, 0.75; 95% CI, 0.65-0.85) and the external validation cohort (AUC, 0.77; 95% CI, 0.72-0.83). We determined a model score threshold demonstrating high negative predictive value (0.95) for death. In addition to a low risk of death, patients below this threshold had shorter ICU length of stay, lower incidence of acute kidney injury, acute respiratory distress syndrome, and need for vasopressors. CONCLUSIONS: We have developed a simple, robust biomarker-based model that identifies patients with SIRS/sepsis at low risk for death and organ dysfunction.
Authors: Matthew M Churpek; Frank J Zadravecz; Christopher Winslow; Michael D Howell; Dana P Edelson Journal: Am J Respir Crit Care Med Date: 2015-10-15 Impact factor: 21.405
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Katie R Famous; Kevin Delucchi; Lorraine B Ware; Kirsten N Kangelaris; Kathleen D Liu; B Taylor Thompson; Carolyn S Calfee Journal: Am J Respir Crit Care Med Date: 2017-02-01 Impact factor: 21.405
Authors: Hector R Wong; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie Fitzgerald; Paul A Checchia; Keith Meyer; Thomas P Shanley; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Shekhar S Raj; Shira Gertz; Emily Dawson; Kelli Howard; Kelli Harmon; Patrick Lahni; Erin Frank; Kimberly W Hart; Christopher J Lindsell Journal: Crit Care Med Date: 2015-08 Impact factor: 7.598
Authors: Kirsi-Maija Kaukonen; Michael Bailey; David Pilcher; D Jamie Cooper; Rinaldo Bellomo Journal: N Engl J Med Date: 2015-03-17 Impact factor: 91.245
Authors: Hector R Wong; Natalie Cvijanovich; Derek S Wheeler; Michael T Bigham; Marie Monaco; Kelli Odoms; William L Macias; Mark D Williams Journal: Am J Respir Crit Care Med Date: 2008-05-29 Impact factor: 21.405
Authors: V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky Journal: JAMA Date: 2012-06-20 Impact factor: 56.272
Authors: Cassianne Robinson-Cohen; Ronit Katz; Brenda L Price; Susanna Harju-Baker; Carmen Mikacenic; Jonathan Himmelfarb; W Conrad Liles; Mark M Wurfel Journal: Crit Care Date: 2016-07-03 Impact factor: 9.097
Authors: Carmen Mikacenic; William O Hahn; Brenda L Price; Susanna Harju-Baker; Ronit Katz; Kevin C Kain; Jonathan Himmelfarb; W Conrad Liles; Mark M Wurfel Journal: PLoS One Date: 2015-10-22 Impact factor: 3.240
Authors: Pavan Kumar Bhatraju; Leila R Zelnick; Ronit Katz; Carmen Mikacenic; Susanna Kosamo; William O Hahn; Victoria Dmyterko; Bryan Kestenbaum; David C Christiani; W Conrad Liles; Jonathan Himmelfarb; Mark M Wurfel Journal: Clin J Am Soc Nephrol Date: 2019-03-27 Impact factor: 8.237
Authors: Nadir Yehya; Julie C Fitzgerald; Katie Hayes; Donglan Zhang; Jenny Bush; Natalka Koterba; Fang Chen; Florin Tuluc; David T Teachey; Fran Balamuth; Simon F Lacey; Jan Joseph Melenhorst; Scott L Weiss Journal: Shock Date: 2022-01-20 Impact factor: 3.533
Authors: Maria Fátima de Paula Ramos; Olvania Basso Oliveira; Alceni do Carmo Morais Monteiro de Barros; Clara Versolato Razvickas; Edson de Andrade Pessoa; Rinaldo Florêncio da Silva; Ana Maria Soares Pereira; Marcia Bastos Convento; Fernanda Teixeira Borges; Nestor Schor Journal: PeerJ Date: 2019-07-09 Impact factor: 2.984